We hypothesize that a combination of these two proteomic platforms in the context of a rigorous, clinically well-defined study design will significantly increase our ability to uncover proteomic blood signatures for downstream PSA reflex tests, thus improving prostate cancer diagnosis. The gene discussed is KLK3; the disease is prostate carcinoma.